Schedule Dispatches

Schedule dispatches give a summary of changes coming out in the next month.

This is an early notification of the changes to be announced in the Update to the Pharmaceutical Schedule.

The full Update is available as a PDF(external link)

The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz

May 2026

New Listings

  • Candesartan cilexetil (Candesartan Viatris) tab 4 mg (p’code 2726440), tab 8 mg (p’code 2726459), tab 16 mg (p’code 2726467) and tab 32 mg (p’code 2726475)
  • Cefalexin (Cefalexin Sandoz) grans for oral liq 25 mg per ml, 100 ml – wastage claimable (p’code 2714078)
  • Ezetimibe with simvastatin (Vytorin) tab 10 mg with simvastatin 40 mg – S29 and wastage claimable (p’code 2727722)
  • Hydralazine hydrochloride (Hydrapres) inj 20 mg ampoule – S29 and wastage claimable (p’code 2728176)
  • Icatibant (Icatibant Lupin) inj 10 mg per ml, 3 ml prefilled syringe – Special Authority – Retail pharmacy (p’code 2720531)
  • Letermovir (Prevymis) tab 240 mg – Special Authority – Retail pharmacy – Wastage claimable (p’code 2630605)
  • Mefenamic acid (Ponstan) cap 250mg (p’code 2720523)
  • Montelukast (Relonchem) tab 5 mg – S29 and wastage claimable (p’code 2728079)
  • Nitrofurantoin (Nitrofurantoin Clinect) tab 50 mg – Up to 30 tab available on a PSO (p’code 2723670)
  • Olanzapine (Olanzapine ODT Viatris) tab orodispersible 5 mg (p’code 2726335) and tab orodispersible 10 mg (p’code 2726327) – Safety medicine; prescriber may determine dispensing frequency – S29 and wastage claimable
  • Pirfenidone (Pirfenidone Sandoz) tab 267 mg (p’code 2715961) and tab 801 mg (p’code 2715988) – Retail pharmacy – Specialist – Special Authority
  • Polyethylene glycol 400 and propylene glycol (Systane Unit Dose) eye drops 0.4% and propylene glycol 0.3%, 0.8 ml – Special Authority – Retail pharmacy (p’code 2718634)
  • Ramipril tab 1.25 mg (p’code 2728192) (Ramipril Viatris), tab 5 mg (p’code 2727854) and tab 10 mg (p’code 2727862) (Ramipril Mylan Generics) – S29 and wastage claimable
  • Salbutamol with ipratropium bromide (Combiprasal) nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 5 ml ampoule – Up to 20 neb available on a PSO – S29 and wastage claimable (p’code 2729512)
  • Venetoclax (Venclexta) tab 50 mg, 7 OP – Retail pharmacy – Specialist – Special Authority (p’code 2696754)

Changes to restrictions, chemical names and presentations

  • Adrenaline (DBL Adrenaline) inj 1 in 10,000, 10 ml ampoule – amended brand name
  • Enoxaparin sodium inj 20 mg in 0.2 ml syringe, inj 40 mg in 0.4 ml syringe, inj 60 mg in 0.6 ml syringe, inj 80 mg in 0.8 ml syringe and inj 100 mg in 1 ml syringe (Clexane) and inj 120 mg in 0.8 ml syringe and inj 150 mg in 1 ml syringe (Clexane Forte) – amended subsidy by endorsement
  • Ibrutinib (Imbruvica) tab 140 mg and 420 mg – amended Special Authority criteria
  • Ipilimumab inj 5 mg per ml, 10 ml vial and inj 5 mg per ml, 40 ml vial (Yervoy) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Nivolumab inj 10 mg per ml, 4 ml vial and inj 10 mg per ml, 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Obinutuzumab inj 25 mg per ml, 40 ml vial (Gazyva) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial – amended Special Authority criteria
  • Pilocarpine nitrate (Minims Pilocarpine) eye drops 2% single dose, 20 dose – amended Special Authority criteria
  • Progesterone (Utrogestan) cap 100 mg – remove stat dispensing
  • Rituximab inj 100 mg per 10 ml vial and inj 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria
  • Venetoclax (Venclexta) tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, 42 OP; tab 10 mg, 2 OP; tab 50 mg, 7 OP and tab 100 mg – amended Special Authority criteria

Increased subsidy

Chemical

Presentation

Fully subsidised brands

Doxorubicin hydrochloride

Inj 2 mg per ml, 25 ml vial

Inj 2 mg per ml, 100 ml vial

Doxorubicin Ebewe

Inj 1 mg for ECP

Baxter

Epirubicin hydrochloride

Inj 2 mg per ml, 25 ml vial

Inj 2 mg per ml, 100 ml vial

Epirubicin Ebewe

Inj 1 mg for ECP

Baxter

Fludarabine phosphate

Inj 50 mg vial

Fludarabine Ebewe

Inj 50 mg for ECP, 50 mg OP

Baxter

Mitozantrone

Inj 2 mg per ml, 10 ml vial

Mitozantrone Ebewe

Inj 1 mg for ECP

Baxter

Decreased subsidy

Chemical

Presentation

Fully subsidised brands

Cefalexin

Grans for oral liq 50 mg per ml, 100 ml

Cefalexin Sandoz